Evidence Hub

Necrotic skin reaction following the administration of intramuscular injections of long-acting cabotegravir/rilpivirine and alternatively-sourced testosterone

Bukhari S, Byrne R, Daramola Y, Antoniadi C, Boffito M

International journal of STD & AIDS, 2025

Abstract

In this case, we describe a 52-year-old man who was switched to long-acting cabotegravir/rilpivirine (CAB/RPV LA) injectable antiretroviral therapy (ART) on a background of well-controlled HIV. He subsequently developed a painful and swollen area on his right ventrogluteal region 10 days after his first CAB/RPV LA injections when he injected alternatively sourced testosterone in the same region. Examination findings showed a firm and defined lump with ecchymosis noted on the skin overlying. His initial blood results did not show any gross abnormalities and an ultrasound of the area was equivocal. After being reviewed in ambulatory care, the emergency department and an outpatient plastic surgery clinic settings over the course of 3 weeks, the swelling and skin changes gradually resolved. He was then switched back to oral ART on subsequent review.

How strong is the evidence?

Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free